Delving into the Latest Updates on Phosphorylcholine monoclonal antibody (Athera Biotechnologies) with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

IgG phosphorylcholine antibody, PC-mAb, PCmab

+ [2]

Target

PC

Mechanism

PC inhibitors(pyruvate carboxylase inhibitors)

Therapeutic Areas

Cardiovascular Diseases

Active Indication

Atherosclerosis

Inactive Indication

ArteritisCoronary RestenosisMyocardial Infarction

Originator Organization

Dyax Corp.

Active Organization

Dyax Corp.

Inactive Organization

Athera Biotechnologies AB

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

Gene Sequence

Sequence Code 212995L

Sequence Code 212990H

Patients with ST-segment elevation myocardial infarction (STEMI) that have suffered a major anterior wall infarction or where coronary blood flow is less than normal in spite of successful percutaneous coronary intervention (PCI) have a poor prognosis. There are today no medical treatments that specifically reduce risk in these patients. The acute inflammatory reaction in conjunction with a STEMI and reperfusion by PCI determines the final size of the infarction and the signals leading to left ventricular remodelling.
This study is designed to assess the efficacy and safety of single intravenous injection with ATH3G10, a fully human IgG1 antibody against phosphorylcholine, in high-risk subjects with STEMI. ATH3G10 aims to reduce inflammation and thereby infarction size and remodeling.

Start Date29 Mar 2019

Sponsor / Collaborator

Athera Biotechnologies AB

NCT03320265 / TerminatedPhase 2

Double-blind, Randomised, Placebo-controlled, Multicentre, Phase IIa Study to Investigate the Effect of PC-mAb on Arterial Inflammation in Subjects With Elevated Lipoprotein a

Inflammation and abnormal amount of lipids in the blood are key factors for the development and progression of atherosclerosis (thickening of the artery wall) and cardiovascular disease. Lipoprotein (a) is a pro-inflammatory plasma lipoprotein that is believed to be a risk factor for cardiovascular diseases. Vascular inflammation generates a range of effects, including endothelial dysfunction and migration of white blood cells into the vessel wall, which results in increased risk of cardiovascular events.
This study is designed to assess the effects of multiple monthly intravenous infusions with the fully human antibody called PC-mAb, in subjects with elevated lipoprotein (a).

Start Date11 Oct 2017

Sponsor / Collaborator

Athera Biotechnologies AB

100 Clinical Results associated with Phosphorylcholine monoclonal antibody (Athera Biotechnologies)

Login to view more data

100 Translational Medicine associated with Phosphorylcholine monoclonal antibody (Athera Biotechnologies)

Login to view more data

100 Patents (Medical) associated with Phosphorylcholine monoclonal antibody (Athera Biotechnologies)

Login to view more data

42

Literatures (Medical) associated with Phosphorylcholine monoclonal antibody (Athera Biotechnologies)

01 Nov 2024·Veterinary Microbiology

Identification of three novel linear B-cell epitopes on VP7 of African horse sickness virus using monoclonal antibodies

Article

Author: Hu, Xinbing ; Guan, Guiquan ; Wang, Xuanying ; Yin, Hong ; Tian, Zhancheng ; Luo, Jianxun ; Du, Junzheng ; Xu, Jing

African horse sickness (AHS) is an acute and subacute infectious disease of equine species caused by the African horse sickness virus (AHSV). The VP7 of AHSV is a group-specific protein conserved in all serotypes and is an excellent candidate for the serological diagnosis and an AHS vaccine component. However, to date, B-cell epitopes on the AHSV VP7 recognized by humoral immune responses remain unclear. This study expressed the recombinant AHSV VP7 soluble in Escherichia coli and purified it for mouse immunization. Four monoclonal antibodies (mAbs) were screened and identified by hybridoma cell fusion, clonal purification, and immunological assays. The B-cell epitopes, recognized by monoclonal antibodies 4B5, 3G10, 3D7, and 4D6, were identified by a series of truncated overlapping peptides expressed as glutathione S-transferase (GST)-fusion proteins. The results revealed that 4B5 recognized the ¹²⁴VQTGRYAGA¹³² motif, 3G10 recognized the ¹⁴⁰RYYVPQGRT¹⁴⁸ motif, while 3D7 and 4D6 recognized the ²⁹²QPINPPIFP³⁰⁰ motif. Amino acid sequence alignment indicated that three novel B-cell epitopes were conserved among various AHSV serotypes but unconserved in other orbiviruses, such as the bluetongue and epidemic hemorrhagic disease viruses. This study informs on the antigenic epitopes of AHSV VP7, facilitating future investigations into the serological diagnosis method and epitope-based vaccines against AHSV.

01 Mar 2024·Environmental Research

A mechanistic approach to arsenic adsorption and immobilization in aqueous solution, groundwater, and contaminated paddy soil using pine-cone magnetic biochar

Article

Author: Mickan, Bede ; Ahmed Khan, Basit ; Ahmad, Mahtab ; Solaiman, Zakaria M ; Bolan, Nanthi ; Farooqi, Abida ; Iqbal, Sajid ; Siddique, Kadambot H M

Arsenic (As) poisoning in groundwater and rice paddy soil has increased globally, impacting human health and food security. There is an urgent need to deal with As-contaminated groundwater and soil. Biochar can be a useful remedy for toxic contaminants. This study explains the synthesis of pinecone-magnetic biochar (PC-MBC) by engineering the pinecone-pristine biochar with iron salts (FeCl₃.6H₂O and FeSO₄.7H₂O) to investigate its effects on As(V) adsorption and immobilization in water and soil, respectively. The results indicated that PC-MBC can remediate As(V)-contaminated water, with an adsorption capacity of 12.14 mg g^-1 in water. Isotherm and kinetic modeling showed that the adsorption mechanism involved multilayer, monolayer, and diffusional processes, with chemisorption operating as the primary interface between As(V) and biochar. Post-adsorption analysis of PC-MBC, using FTIR and XRD, further revealed chemical fixing and outer-sphere complexation between As(V) and Fe, O, NH, and OH as the main reasons for As(V) adsorption onto PC-MBC. Recycling of PC-MBC also had excellent adsorption even after several regeneration cycles. Similarly, PC-MBC successfully immobilized As in paddy soil. Single and sequential extraction results showed the transformation of mobile forms of As to a more stable form, confirmed by non-destructive analysis using SEM, EDX, and elemental dot mapping. Thus, Fe-modified pine-cone biochar could be a suitable and cheap adsorbent for As-contaminated water and soil.

01 Feb 2024·Auris Nasus Larynx

Application of phosphorylcholine derivative as mucosal adjuvant enhancing mucosal immune responses in the upper respiratory tract

Article

Author: Kurono, Yuichi ; Hirano, Takashi ; Yamashita, Masaru ; Jimura, Tomohiro ; Kawabata, Masaki

OBJECTIVEA phosphorylcholine (PC)-derivative with high binding ability (PCDB) was intranasally administered to mice with ovalbumin (OVA), and immune responses were investigated to determine whether PCDB has antigenicity and adjuvanticity.METHODSBALB/c mice were intranasally immunized with PCDB coupled with OVA, unbound PCDB plus OVA, cholera toxin (CT) plus OVA, OVA alone, and PCDB alone. Then, the production of OVA- and PC-specific antibodies in external secretions and serum, and the secretion of cytokines such as IL-4 and IFN-γ from splenic mononuclear cells by stimulation with PCDB and OVA were examined. Furthermore, the secretion of IL-12p40 from CD11c⁺ cells following stimulation with PCDB was observed to clarify the adjuvant effect of PCDB through TLR4.RESULTSIntranasal immunization with PCDB plus OVA increased OVA- and PC-specific IgA in external secretions and OVA- and PC-specific antibodies in the serum. The analysis of IgG subclasses specific to OVA and PC showed a higher production of IgG1 than IgG2, and the secretion of both IL-4 and IFN-γ was enhanced. However, IL-12p40 secretion from CD11c⁺ cells was increased and OVA-specific IgE production was not promoted by PCDB stimulation.CONCLUSIONIntranasal administration of the protein antigen with PCDB enhanced immune responses specific to the mixed antigen and PC. Although PCDB acted to bias the immune response toward the Th2-type, antigen-specific IgE production did not increase. These findings suggest that PCDB has the potential to be a mucosal vaccine with both adjuvanticity and antigenicity without causing side effects due to type I allergy.

100 Deals associated with Phosphorylcholine monoclonal antibody (Athera Biotechnologies)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Atherosclerosis	Phase 2	-	Dyax Corp.	-
Arteritis	Phase 1	SE	Athera Biotechnologies AB	11 Oct 2017
Arteritis	Phase 1	NL	Athera Biotechnologies AB	11 Oct 2017
Myocardial Infarction	Discovery	NL	Athera Biotechnologies AB	26 Mar 2019
Coronary Restenosis	Discovery	SE	Athera Biotechnologies AB	-